{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:53:04Z","timestamp":1777953184539,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Science and Technology Department of National Administration of Traditional Chinese Medicine & Zhejiang Provincial Administration of Traditional Chinese Medicine","award":["GZY-ZJ-KJ-23032"],"award-info":[{"award-number":["GZY-ZJ-KJ-23032"]}]},{"name":"Research Initiation Project of the Eye Hospital, School of Ophthalmology & Optometry, Wenzhou Medical University","award":["KYQD20230901"],"award-info":[{"award-number":["KYQD20230901"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81402839"],"award-info":[{"award-number":["81402839"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11494-6","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T11:24:02Z","timestamp":1772364242000},"page":"2801-2816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ligand-based graph neural network, molecular dynamics and biological evaluation for identification of potential FGFR1 kinase inhibitors"],"prefix":"10.1007","volume":"30","author":[{"given":"Tao","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongliang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yucan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wulan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,1]]},"reference":[{"key":"11494_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham MJ, Murtola T, Schulz R et al (2015) Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u20132:19\u201325. https:\/\/doi.org\/10.1016\/j.softx.2015.06.001","journal-title":"SoftwareX"},{"key":"11494_CR2","doi-asserted-by":"crossref","unstructured":"Adasme MF, Linnemann KL, Bolz SN et al (2021) Plip 2021: expanding the scope of the protein-ligand interaction profiler to dna and rna. Nucleic Acids Res 49(W1):W530\u2013W534. https:\/\/doi.org\/10.1093\/nar\/gkab294https:\/\/plip-tool.biotec.tu-dresden.de\/plip-web\/plip\/index","DOI":"10.1093\/nar\/gkab294"},{"issue":"5","key":"11494_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina IS, Turner NC (2017) Advances and challenges in targeting fgfr signalling in cancer. Nat Rev Cancer 17(5):318\u2013332. https:\/\/doi.org\/10.1038\/nrc.2017.8","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"11494_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd2792","volume":"8","author":"A Beenken","year":"2009","unstructured":"Beenken A, Mohammadi M (2009) The fgf family: biology, pathophysiology and therapy. Nat Rev Drug Discovery 8(3):235\u201353. https:\/\/doi.org\/10.1038\/nrd2792","journal-title":"Nat Rev Drug Discovery"},{"issue":"10","key":"11494_CR5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","volume":"30","author":"BR Brooks","year":"2009","unstructured":"Brooks BR, Brooks Iii CL, Mackerell AD Jr et al (2009) Charmm: The biomolecular simulation program. J Comput Chem 30(10):1545\u20131614. https:\/\/doi.org\/10.1002\/jcc.21287","journal-title":"J Comput Chem"},{"issue":"D1","key":"11494_CR6","doi-asserted-by":"publisher","first-page":"D564","DOI":"10.1093\/nar\/gkae1091","volume":"53","author":"SK Burley","year":"2024","unstructured":"Burley SK, Bhatt R, Bhikadiya C et al (2024) Updated resources for exploring experimentally-determined pdb structures and computed structure models at the rcsb protein data bank. Nucleic Acids Res 53(D1):D564\u2013D574. https:\/\/doi.org\/10.1093\/nar\/gkae1091","journal-title":"Nucleic Acids Res"},{"key":"11494_CR7","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s11030-023-10714-7","volume":"28","author":"ES Charan","year":"2024","unstructured":"Charan ES, Sharma A, Sandhu H et al (2024) Fgfr1pred: an artificial intelligence-based model for predicting fibroblast growth factor receptor 1 inhibitor. Mol Diversity 28:2065\u20132076. https:\/\/doi.org\/10.1007\/s11030-023-10714-7","journal-title":"Mol Diversity"},{"issue":"7966","key":"11494_CR8","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41586-023-06155-9","volume":"618","author":"L Chen","year":"2023","unstructured":"Chen L, Fu L, Sun J et al (2023) Structural basis for fgf hormone signalling. Nature 618(7966):862\u2013870. https:\/\/doi.org\/10.1038\/s41586-023-06155-9","journal-title":"Nature"},{"key":"11494_CR9","doi-asserted-by":"publisher","unstructured":"Chioni AM, Grose RP (2021) Biological significance and targeting of the fgfr axis in cancer. Cancers (Basel) 13(22). https:\/\/doi.org\/10.3390\/cancers13225681","DOI":"10.3390\/cancers13225681"},{"key":"11494_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-1-4939-9869-2_17","volume":"2073","author":"TA Collier","year":"2020","unstructured":"Collier TA, Piggot TJ, Allison JR (2020) Molecular dynamics simulation of proteins. Methods Mol Biol 2073:311\u2013327. https:\/\/doi.org\/10.1007\/978-1-4939-9869-2_17","journal-title":"Methods Mol Biol"},{"issue":"4","key":"11494_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/1535-7163.MCT-15-1010","volume":"16","author":"J Datta","year":"2017","unstructured":"Datta J, Damodaran S, Parks H et al (2017) Akt activation mediates acquired resistance to fibroblast growth facto r receptor inhibitor bgj398. Mol Cancer Ther 16(4):614\u2013624. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-1010","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"11494_CR12","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/annonc\/mdt419","volume":"25","author":"R Dienstmann","year":"2014","unstructured":"Dienstmann R, Rodon J, Prat A et al (2014) Genomic aberrations in the fgfr pathway: opportunities for targeted th erapies in solid tumors. Annals of oncology official journal of the European Society for Medi cal Oncology 25(3):552\u2013563. https:\/\/doi.org\/10.1093\/annonc\/mdt419","journal-title":"Annals of oncology official journal of the European Society for Medi cal Oncology"},{"issue":"1","key":"11494_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du Z, Lovly CM (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17(1):58. https:\/\/doi.org\/10.1186\/s12943-018-0782-4","journal-title":"Mol Cancer"},{"key":"11494_CR14","doi-asserted-by":"publisher","unstructured":"Eberhardt J, Santos-Martins D, Tillack AF et al. (2021) Autodock vina 1.2.0: New docking methods, expanded force field, and py thon bindings. J Chem Inf Model 61(8), 3891\u20133898. https:\/\/doi.org\/10.1021\/acs.jcim.1c00203","DOI":"10.1021\/acs.jcim.1c00203"},{"issue":"2","key":"11494_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","volume":"16","author":"VP Eswarakumar","year":"2005","unstructured":"Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine & Growth Factor Reviews 16(2):139\u201349. https:\/\/doi.org\/10.1016\/j.cytogfr.2005.01.001","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"7","key":"11494_CR16","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner RA, Banks JL, Murphy RB et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. meth od and assessment of docking accuracy. J Med Chem 47(7):1739\u201349. https:\/\/doi.org\/10.1021\/jm0306430","journal-title":"J Med Chem"},{"key":"11494_CR17","doi-asserted-by":"crossref","unstructured":"Fu L, Shi S, Yi J et al (2024) Admetlab 3.0: an updated comprehensive online admet prediction platform enhanced with broader coverage, improved performance, api functionality and decision support. Nucleic Acids Res 52(W1), W422\u2013W431. https:\/\/doi.org\/10.1093\/nar\/gkae236https:\/\/admetlab3.scbdd.com\/","DOI":"10.1093\/nar\/gkae236"},{"issue":"D1","key":"11494_CR18","doi-asserted-by":"publisher","first-page":"D1045","DOI":"10.1093\/nar\/gkv1072","volume":"44","author":"MK Gilson","year":"2015","unstructured":"Gilson MK, Liu T, Baitaluk M et al (2015) Bindingdb in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res 44(D1):D1045\u2013D1053. https:\/\/doi.org\/10.1093\/nar\/gkv1072","journal-title":"Nucleic Acids Res"},{"issue":"16","key":"11494_CR19","doi-asserted-by":"publisher","first-page":"7584","DOI":"10.1080\/07391102.2021.1899049","volume":"40","author":"L Huang","year":"2022","unstructured":"Huang L, Wu X, Fu X et al (2022) Ligand based 3d-qsar model, pharmacophore, molecular docking and adme to identify potential fibroblast growth factor receptor 1 inhibitors. J Biomol Struct Dyn 40(16):7584\u20137597. https:\/\/doi.org\/10.1080\/07391102.2021.1899049","journal-title":"J Biomol Struct Dyn"},{"issue":"10","key":"11494_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle M, Roychowdhury S, Kelley RK et al (2021) Infigratinib (bgj398) in previously treated patients with advanced or metastatic cholangiocarcinoma with fgfr2 fusions or rearrangements: ma ture results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 6(10):803\u2013815. https:\/\/doi.org\/10.1016\/S2468-1253(21)00196-5","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"23","key":"11494_CR21","doi-asserted-by":"publisher","first-page":"13153","DOI":"10.1080\/07391102.2023.2274975","volume":"42","author":"A Kaur","year":"2024","unstructured":"Kaur A, Mandal D (2024) Computational identification and exploration of novel fgfr tyrosine ki nase inhibitors for the treatment of cholangiocarcinoma. J Biomol Struct Dyn 42(23):13153\u201313164. https:\/\/doi.org\/10.1080\/07391102.2023.2274975","journal-title":"J Biomol Struct Dyn"},{"key":"11494_CR22","unstructured":"Kipf TN, Welling M (2016) Semi-supervised classification with graph convolutional networks. arxive preprint 10.48550\/arXiv. 1609.02907"},{"issue":"6","key":"11494_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(15)70159-2","volume":"16","author":"GE Konecny","year":"2015","unstructured":"Konecny GE, Finkler N, Garcia AA et al (2015) Second-line dovitinib (tki258) in patients with fgfr2-mutated or fgfr2 -non-mutated advanced or metastatic endometrial cancer: a non-randomis ed, open-label, two-group, two-stage, phase 2 study. Lancet Oncol 16(6):686\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(15)70159-2","journal-title":"Lancet Oncol"},{"issue":"4","key":"11494_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40265-025-02153-5","volume":"85","author":"YN Lamb","year":"2025","unstructured":"Lamb YN (2025) Tasurgratinib succinate: First approval. Drugs 85(4):585\u2013590. https:\/\/doi.org\/10.1007\/s40265-025-02153-5","journal-title":"Drugs"},{"key":"11494_CR25","doi-asserted-by":"publisher","unstructured":"Landrum G, Tosco P, Kelle B (2022) Rdkit: Open-source cheminformatics. https:\/\/doi.org\/10.5281\/zenodo.6605135","DOI":"10.5281\/zenodo.6605135"},{"key":"11494_CR26","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.7234","volume":"7","author":"J Liu","year":"2019","unstructured":"Liu J, Zhu L, Zhang X et al (2019) Peptide-based nta(ni)-nanodiscs for studying membrane enhanced fgfr1 kinase activities. PeerJ 7:e7234. https:\/\/doi.org\/10.7717\/peerj.7234","journal-title":"PeerJ"},{"key":"11494_CR27","doi-asserted-by":"crossref","unstructured":"Liu T, Hwang L, Burley SK et al (2024) Bindingdb in 2024: a fair knowledgebase of protein-small molecule binding data. Nucleic Acids Res 53(D1):D1633\u2013D1644. https:\/\/doi.org\/10.1093\/nar\/gkae1075https:\/\/www.bindingdb.org\/rwd\/bind\/index.jsp","DOI":"10.1093\/nar\/gkae1075"},{"issue":"4","key":"11494_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH et al (2019) Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 381(4):338\u2013348. https:\/\/doi.org\/10.1056\/NEJMoa1817323","journal-title":"N Engl J Med"},{"issue":"6","key":"11494_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrd2111","volume":"6","author":"MP Mazanetz","year":"2007","unstructured":"Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discovery 6(6):464\u2013479. https:\/\/doi.org\/10.1038\/nrd2111","journal-title":"Nat Rev Drug Discovery"},{"issue":"2","key":"11494_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cytogfr.2005.01.008","volume":"16","author":"M Mohammadi","year":"2005","unstructured":"Mohammadi M, Olsen SK, Ibrahimi OA (2005) Structural basis for fibroblast growth factor receptor activation. Cytokine & Growth Factor Reviews 16(2):107\u201337. https:\/\/doi.org\/10.1016\/j.cytogfr.2005.01.008","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"5","key":"11494_CR31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","volume":"15","author":"B Nolen","year":"2004","unstructured":"Nolen B, Taylor S, Ghosh G (2004) Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 15(5):661\u201375. https:\/\/doi.org\/10.1016\/j.molcel.2004.08.024","journal-title":"Mol Cell"},{"issue":"14","key":"11494_CR32","doi-asserted-by":"publisher","first-page":"13880","DOI":"10.1021\/acsomega.4c08366","volume":"10","author":"J Patra","year":"2025","unstructured":"Patra J, Keshari AK, Bhandare RR et al (2025) Discovery of novel multiangiogenic agents targeting vegfr2, ephb4, fgfr-1, and tie-2: Receptor-based pharmacophore modeling, virtual screening, and molecular modeling studies. ACS Omega 10(14):13880\u201313897. https:\/\/doi.org\/10.1021\/acsomega.4c08366","journal-title":"ACS Omega"},{"issue":"1","key":"11494_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1039\/c5cp05142h","volume":"18","author":"D Radziuk","year":"2016","unstructured":"Radziuk D, M\u00f6hwald H (2016) Ultrasonically treated liquid interfaces for progress in cleaning and separation processes. Phys Chem Chem Phys 18(1):21\u201346. https:\/\/doi.org\/10.1039\/c5cp05142h","journal-title":"Phys Chem Chem Phys"},{"issue":"40","key":"11494_CR34","doi-asserted-by":"publisher","first-page":"14344","DOI":"10.1073\/pnas.0507200102","volume":"102","author":"V Rand","year":"2005","unstructured":"Rand V, Huang J, Stockwell T et al (2005) Sequence survey of receptor tyrosine kinases reveals mutations in glio blastomas. Proceedings of the National Academy of Sciences of the United States o f America 102(40):14344\u20139. https:\/\/doi.org\/10.1073\/pnas.0507200102","journal-title":"Proceedings of the National Academy of Sciences of the United States o f America"},{"key":"11494_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104567","volume":"151","author":"R JRobert","year":"2020","unstructured":"JRobert R (2020) The role of fibroblast growth factor receptor (fgfr) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the u rinary bladder. Pharmacol Res 151:104567. https:\/\/doi.org\/10.1016\/j.phrs.2019.104567","journal-title":"Pharmacol Res"},{"key":"11494_CR36","doi-asserted-by":"crossref","unstructured":"Satoh T, Barth\u00e9l\u00e9my P, Nogova L, et al. (2025) Phase 2 study of futibatinib in patients with gastric or gastroesophag eal junction cancer harboring fgfr2 amplifications. European journal of cancer (Oxford, England : 1990) 218:115262. DOI: 10.1016\/j.ejca.2025.115262IF: 7.1 Q1 B1","DOI":"10.1016\/j.ejca.2025.115262"},{"key":"11494_CR37","unstructured":"Schr\u00f6dinger L, DeLano W (2022) Pymol. http:\/\/www.pymol.org\/pymol"},{"issue":"14","key":"11494_CR38","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/sj.onc.1210007","volume":"26","author":"RX Shao","year":"2007","unstructured":"Shao RX, Kato N, Lin LJ et al (2007) Absence of tyrosine kinase mutations in japanese colorectal cancer pat ients. Oncogene 26(14):2133\u20135. https:\/\/doi.org\/10.1038\/sj.onc.1210007","journal-title":"Oncogene"},{"issue":"6099","key":"11494_CR39","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1126\/science.1220834","volume":"337","author":"D Singh","year":"2012","unstructured":"Singh D, Chan JM, Zoppoli P et al (2012) Transforming fusions of fgfr and tacc genes in human glioblastoma. Science (New York NY) 337(6099):1231\u20135. https:\/\/doi.org\/10.1126\/science.1220834","journal-title":"Science (New York NY)"},{"issue":"5","key":"11494_CR40","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Iannotti NO, Gutierrez M et al (2022) Fight-101, a first-in-human study of potent and selective fgfr 1\u20133 inh ibitor pemigatinib in pan-cancer patients with fgf\/fgfr alterations an d advanced malignancies. Ann Oncol 33(5):522\u2013533. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.001","journal-title":"Ann Oncol"},{"key":"11494_CR41","doi-asserted-by":"publisher","unstructured":"Torabi M, Sardari S, Rodr\u00edguez-Mart\u00ednez A et al (2025) Drug repurposing to identify potential fda-approved drugs targeting th ree main angiogenesis receptors through a deep learning framework. Mol Diversity pp https:\/\/doi.org\/10.1007\/s11030-025-11214-6","DOI":"10.1007\/s11030-025-11214-6"},{"issue":"12","key":"11494_CR42","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","volume":"21","author":"M Touat","year":"2015","unstructured":"Touat M, Ileana E, Postel-Vinay S et al (2015) Targeting fgfr signaling in cancer. Clin Cancer Res 21(12):2684\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2329","journal-title":"Clin Cancer Res"},{"issue":"12","key":"11494_CR43","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.str.2014.09.019","volume":"22","author":"J Tucker","year":"2014","unstructured":"Tucker J, Klein T, Breed J et al (2014) Structural insights into fgfr kinase isoform selectivity: Diverse binding modes of azd4547 and ponatinib in complex with fgfr1 and fgfr4. Structure 22(12):1764\u20131774. https:\/\/doi.org\/10.1016\/j.str.2014.09.019","journal-title":"Structure"},{"issue":"2","key":"11494_CR44","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2):116\u2013129. https:\/\/doi.org\/10.1038\/nrc2780","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"11494_CR45","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","unstructured":"Vald\u00e9s-Tresanco MS, Vald\u00e9s-Tresanco ME, Valiente PA et al (2021) gmx_mmpbsa: A new tool to perform end-state free energy calculations with gromacs. J Chem Theory Comput 17(10):6281\u20136291. https:\/\/doi.org\/10.1021\/acs.jctc.1c00645","journal-title":"J Chem Theory Comput"},{"issue":"12","key":"11494_CR46","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1021\/ci300363c","volume":"52","author":"K Vanommeslaeghe","year":"2012","unstructured":"Vanommeslaeghe K, MacKerell JAD (2012) Automation of the charmm general force field (cgenff) i: Bond perception and atom typing. J Chem Inf Model 52(12):3144\u20133154. https:\/\/doi.org\/10.1021\/ci300363c","journal-title":"J Chem Inf Model"},{"issue":"12","key":"11494_CR47","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1021\/ci3003649","volume":"52","author":"K Vanommeslaeghe","year":"2012","unstructured":"Vanommeslaeghe K, Raman EP, MacKerell JAD (2012) Automation of the charmm general force field (cgenff) ii: Assignment of bonded parameters and partial atomic charges. J Chem Inf Model 52(12):3155\u20133168. https:\/\/doi.org\/10.1021\/ci3003649","journal-title":"J Chem Inf Model"},{"key":"11494_CR48","unstructured":"Veli\u010dkovi\u0107 P, Cucurull G, Casanova A et al (2017) Graph attention networks. arxive preprint 1048550\/arXiv.1710.10903"},{"key":"11494_CR49","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1186\/s12885-015-2000-8","volume":"15","author":"M Verstraete","year":"2015","unstructured":"Verstraete M, Debucquoy A, Gonnissen A et al (2015) In vitro and in vivo evaluation of the radiosensitizing effect of a se lective fgfr inhibitor (jnj-42756493) for rectal cancer. BMC Cancer 15:946. https:\/\/doi.org\/10.1186\/s12885-015-2000-8","journal-title":"BMC Cancer"},{"issue":"1","key":"11494_CR50","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1021\/jm501603h","volume":"58","author":"RS Vijayan","year":"2015","unstructured":"Vijayan RS, He P, Modi V et al (2015) Conformational analysis of the dfg-out kinase motif and biochemical profiling of structurally validated type ii inhibitors. J Med Chem 58(1):466\u201379. https:\/\/doi.org\/10.1021\/jm501603h","journal-title":"J Med Chem"},{"issue":"1","key":"11494_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2013.10.016","volume":"344","author":"Y Wang","year":"2014","unstructured":"Wang Y, Cai Y, Ji J et al (2014) Discovery and identification of new non-atp competitive fgfr1 inhibitors with therapeutic potential on non-small-cell lung cancer. Cancer Lett 344(1):82\u201389. https:\/\/doi.org\/10.1016\/j.canlet.2013.10.016","journal-title":"Cancer Lett"},{"issue":"4","key":"11494_CR52","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.fmre.2024.02.011","volume":"4","author":"H Wu","year":"2024","unstructured":"Wu H, Liu J, Zhang R et al (2024) A review of deep learning methods for ligand based drug virtual screen ing. Fundam Res 4(4):715\u2013737. https:\/\/doi.org\/10.1016\/j.fmre.2024.02.011","journal-title":"Fundam Res"},{"issue":"15","key":"11494_CR53","doi-asserted-by":"publisher","first-page":"10666","DOI":"10.1021\/acs.jmedchem.1c00713","volume":"64","author":"L Wu","year":"2021","unstructured":"Wu L, Zhang C, He C et al (2021) Discovery of pemigatinib: A potent and selective fibroblast growth fac tor receptor (fgfr) inhibitor. J Med Chem 64(15):10666\u201310679. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00713","journal-title":"J Med Chem"},{"issue":"10","key":"11494_CR54","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.7150\/thno.68972","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi Z, Li J et al (2022) Fgfr blockade boosts t cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics 12(10):4564\u20134580. https:\/\/doi.org\/10.7150\/thno.68972","journal-title":"Theranostics"},{"issue":"8","key":"11494_CR55","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2174\/1386207013330670","volume":"4","author":"C Xi","year":"2001","unstructured":"Xi C, Ming L, Michael KG (2001) Bindingdb: A web-accessible molecular recognition database. Combinatorial Chemistry & High Throughput Screening 4(8):719\u2013725. https:\/\/doi.org\/10.2174\/1386207013330670","journal-title":"Combinatorial Chemistry & High Throughput Screening"},{"issue":"17","key":"11494_CR56","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.4155\/fmc-2018-0103","volume":"10","author":"W Xue","year":"2018","unstructured":"Xue W, Li M, Chen L et al (2018) Recent developments and advances of fgfr as a potential target in canc er. Future Med Chem 10(17):2109\u20132126. https:\/\/doi.org\/10.4155\/fmc-2018-0103","journal-title":"Future Med Chem"},{"issue":"1","key":"11494_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","volume":"31","author":"K Zhang","year":"2025","unstructured":"Zhang K, Yang X, Wang Y et al (2025) Artificial intelligence in drug development. Nat Med 31(1):45\u201359. https:\/\/doi.org\/10.1038\/s41591-024-03434-4","journal-title":"Nat Med"},{"issue":"6","key":"11494_CR58","doi-asserted-by":"publisher","first-page":"13407","DOI":"10.3390\/ijms160613407","volume":"16","author":"N Zhou","year":"2015","unstructured":"Zhou N, Xu Y, Liu X et al (2015) Combinatorial pharmacophore-based 3d-qsar analysis and virtual screeni ng of fgfr1 inhibitors. Int J Mol Sci 16(6):13407\u201326. https:\/\/doi.org\/10.3390\/ijms160613407","journal-title":"Int J Mol Sci"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11494-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11494-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11494-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:27:16Z","timestamp":1777904836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11494-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["11494"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11494-6","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}